251 related articles for article (PubMed ID: 24330717)
1. Epigenetic silencing of glutaminase 2 in human liver and colon cancers.
Zhang J; Wang C; Chen M; Cao J; Zhong Y; Chen L; Shen HM; Xia D
BMC Cancer; 2013 Dec; 13():601. PubMed ID: 24330717
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer.
Chen M; Zhang J; Li N; Qian Z; Zhu M; Li Q; Zheng J; Wang X; Shi G
PLoS One; 2011; 6(10):e25564. PubMed ID: 22039417
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status.
Szeliga M; Bogacińska-Karaś M; Kuźmicz K; Rola R; Albrecht J
Mol Carcinog; 2016 Sep; 55(9):1309-16. PubMed ID: 26258493
[TBL] [Abstract][Full Text] [Related]
4. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma.
Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z
Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors.
Yu J; Tao Q; Cheung KF; Jin H; Poon FF; Wang X; Li H; Cheng YY; Röcken C; Ebert MP; Chan AT; Sung JJ
Hepatology; 2008 Aug; 48(2):508-18. PubMed ID: 18666234
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of T-box transcription factor 5, a novel tumor suppressor gene, is associated with colon cancer.
Yu J; Ma X; Cheung KF; Li X; Tian L; Wang S; Wu CW; Wu WK; He M; Wang M; Ng SS; Sung JJ
Oncogene; 2010 Dec; 29(49):6464-74. PubMed ID: 20802524
[TBL] [Abstract][Full Text] [Related]
7. SIP1 is downregulated in hepatocellular carcinoma by promoter hypermethylation.
Acun T; Oztas E; Yagci T; Yakicier MC
BMC Cancer; 2011 Jun; 11():223. PubMed ID: 21645397
[TBL] [Abstract][Full Text] [Related]
8. p63 regulates glutaminase 2 expression.
Giacobbe A; Bongiorno-Borbone L; Bernassola F; Terrinoni A; Markert EK; Levine AJ; Feng Z; Agostini M; Zolla L; Agrò AF; Notterman DA; Melino G; Peschiaroli A
Cell Cycle; 2013 May; 12(9):1395-405. PubMed ID: 23574722
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.
Qiu W; Zhou B; Zou H; Liu X; Chu PG; Lopez R; Shih J; Chung C; Yen Y
Am J Pathol; 2004 Nov; 165(5):1689-99. PubMed ID: 15509538
[TBL] [Abstract][Full Text] [Related]
10. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
11. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
Zhao R; Wang N; Huang H; Ma W; Yan Q
Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of dual oxidase 1 by promoter hypermethylation in human hepatocellular carcinoma.
Ling Q; Shi W; Huang C; Zheng J; Cheng Q; Yu K; Chen S; Zhang H; Li N; Chen M
Am J Cancer Res; 2014; 4(5):508-17. PubMed ID: 25232492
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation leads to bone morphogenetic protein 6 downregulation in hepatocellular carcinoma.
He Y; Cui Y; Xu B; Gu J; Wang W; Luo X
PLoS One; 2014; 9(1):e87994. PubMed ID: 24498236
[TBL] [Abstract][Full Text] [Related]
14. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
16. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
[TBL] [Abstract][Full Text] [Related]
18. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
19. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma.
Zhou Y; Qiu XP; Li ZH; Zhang S; Rong Y; Yang GH; Fang-Zheng
Gene; 2019 Jan; 683():35-40. PubMed ID: 30292871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
